Skip to main content
Premium Trial:

Request an Annual Quote

Denmark's Chr. Hansen, Integrated Genomics to Sequence Probiotic Lactic Acid Bacterium

NEW YORK (GenomeWeb News) - Integrated Genomics said yesterday that it has signed an agreement with Danish food ingredients company Chr. Hansen to sequence the genome of an undisclosed probiotic lactic acid bacterium.
This contract extends an ongoing partnership between the companies in lactic acid microbial genomics. Chr. Hansen has also renewed its license to Integrated Genomics’ ERGO microbial genomics bioinformatics system, which it originally licensed in 2004.
Chr. Hansen scientists will use the sequence of the new genome along with ERGO to develop lactic acid bacteria used in foods and as probiotics for human health.
"We will use the information to get a better understanding of the organism in our processes, in those of our customers, as well as to understand the interaction between the probiotic lactic acid bacterium and the host, Eric Johansen, vice president of molecular microbiology at Chr. Hansen, said in a statement. “Ultimately we hope to understand how this specific microorganism provides its documented benefits and look for ways to further improve products containing this strain.”
The companies said they expect the sequencing project to run through 2006.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.